Genomic Health, Inc. (GHDX) Expected to Post Earnings of $0.07 Per Share
Wall Street brokerages expect Genomic Health, Inc. (NASDAQ:GHDX) to report earnings of $0.07 per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Genomic Health’s earnings, with the lowest EPS estimate coming in at $0.05 and the highest estimate coming in at $0.10. Genomic Health posted earnings of $0.03 per share in the same quarter last year, which indicates a positive year over year growth rate of 133.3%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Genomic Health will report full year earnings of $0.56 per share for the current financial year, with EPS estimates ranging from $0.46 to $0.69. For the next financial year, analysts forecast that the firm will report earnings of $0.77 per share, with EPS estimates ranging from $0.47 to $0.95. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Genomic Health.
Genomic Health (NASDAQ:GHDX) last issued its earnings results on Thursday, August 2nd. The medical research company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.07 by $0.19. The company had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $92.23 million. Genomic Health had a net margin of 1.18% and a return on equity of 9.09%. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.08) EPS.
Shares of Genomic Health stock traded up $1.11 on Tuesday, hitting $62.28. 308,000 shares of the company’s stock traded hands, compared to its average volume of 254,496. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of 6,228.00 and a beta of 0.44. Genomic Health has a one year low of $26.54 and a one year high of $62.47.
In other news, insider Steven Shak sold 5,500 shares of the business’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $50.22, for a total value of $276,210.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fred E. Cohen sold 8,250 shares of the company’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $56.22, for a total transaction of $463,815.00. Following the completion of the transaction, the director now directly owns 75,572 shares of the company’s stock, valued at $4,248,657.84. The disclosure for this sale can be found here. Insiders sold a total of 113,279 shares of company stock valued at $5,974,932 in the last three months. 45.80% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Genomic Health by 3.6% in the 2nd quarter. BlackRock Inc. now owns 2,002,972 shares of the medical research company’s stock worth $100,949,000 after purchasing an additional 68,691 shares during the period. Millennium Management LLC boosted its stake in Genomic Health by 114.0% in the 2nd quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock worth $72,891,000 after purchasing an additional 770,413 shares during the period. Renaissance Technologies LLC boosted its stake in Genomic Health by 18.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,404,924 shares of the medical research company’s stock worth $70,808,000 after purchasing an additional 222,324 shares during the period. Point72 Asset Management L.P. boosted its stake in Genomic Health by 136.0% in the 1st quarter. Point72 Asset Management L.P. now owns 388,400 shares of the medical research company’s stock worth $12,153,000 after purchasing an additional 223,800 shares during the period. Finally, Northern Trust Corp boosted its stake in Genomic Health by 0.6% in the 1st quarter. Northern Trust Corp now owns 269,424 shares of the medical research company’s stock worth $8,430,000 after purchasing an additional 1,608 shares during the period. 89.33% of the stock is owned by hedge funds and other institutional investors.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Recommended Story: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.